Amplia Therapeutics Limited

Company Profile

Sector

Healthcare

Industry

Biotechnology

Employees

N/A

Website

www.ampliatx.com

Country

Australia

Exchange

ASX

Amplia Therapeutics Limited, a clinical-stage drug development company develops focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2b clinical trial for pancreatic cancer; and treatment of ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications.

Formerly known as Innate Immunotherapeutics Limited, the company rebranded as Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.

Key Stats

52-Week Range

A$0.10A$0.28

Beta-0.39

Trailing P/EN/A

Forward P/E-20.83

Trailing EPS-0.02

Avg Volume

Earnings & Analyst

Next EarningsN/A

EPS EstimateN/A

Target Mean PriceA$0.42

RecommendationNone

Recommendation MeanN/A

Recent SEC Filings

SEC filings for this ticker are not available yet.